Diversified Healthcare Trust (DHC) Q1 FFO Recovery Tests Bearish Loss Concerns

Investors watching Diversified Healthcare Trust (DHC) got fresh numbers for Q1 2026, with funds from operations (FFO) of US$22.8 million and FFO per share of US$0.09 setting the tone for the latest update. Over recent quarters the company has seen quarterly FFO move from US$11.8 million in Q4 2024 to US$13.6 million in Q2 2025, then to US$4.9 million in Q4 2025 before reaching US$22.8 million in Q1 2026. Trailing twelve month FFO per share sits at US$0.15 against a backdrop of continuing net losses. For you as a shareholder or potential investor, a key question is whether this FFO profile can gradually support healthier margins and narrow the gap between operating cash generation and accounting losses.

See our full analysis for Diversified Healthcare Trust.

With the latest numbers in place, the next step is to see how this earnings story lines up with the widely followed narratives around growth potential, risks, and recovery prospects for DHC.

See what the community is saying about Diversified Healthcare Trust

FFO Turning Positive While Net Losses Persist

• Over the last twelve months, DHC generated US$35.4 million in FFO, or US$0.15 per share, while remaining loss making at the net income line with a trailing loss of US$285.9 million and a five year trend of losses growing about 34.6% per year.
• What stands out for the bullish narrative that focuses on improving portfolio quality and cash flows is that FFO is positive on a trailing basis, yet:
  • Revenue over the last year is described as growing about 5.2% per year, but forecasts still do not show a return to profit in the next three years, which limits the support those cash flows give to the optimistic earnings story.
  • Bulls point to higher quality assets and refinancing as potential earnings drivers, but the data here still shows ongoing accounting losses and no profitability expected in that three year window, so the improvement they are counting on is not yet visible in reported earnings.

Analysts who are positive on DHC argue that FFO traction could be the early sign of the portfolio shift they expect to matter most for long term value, and you can see how that view stacks up against detailed assumptions in the 🐂 Diversified Healthcare Trust Bull Case.

Valuation Gap Versus DCF Fair Value

• DHC trades at a P/S of 1.3x compared with a peer average of 7x and an industry average of 5.6x, and the current share price of US$8.17 sits below the DCF fair value of about US$12.98, which is roughly a 37% gap to that estimate.
• Bears, who focus on high leverage and persistent losses, would argue that this apparent discount reflects real financial strain, and the figures here leave room for that concern:
  • The company is expected to stay unprofitable for at least the next three years, so the low P/S multiple and discount to the DCF fair value are appearing alongside a multi year loss pattern rather than a clear profit base.
  • Losses growing around 34.6% per year over five years suggest that, for cautious investors, the valuation gap alone is not enough without clearer evidence that those losses are stabilising or reversing.

Skeptics who worry that balance sheet pressure and ongoing losses justify a low multiple may want to see how that cautious stance is laid out in the full bear case before forming a view on the current discount 🐻 Diversified Healthcare Trust Bear Case.

Modest Revenue Growth, Ongoing Loss Trend

• Revenue has been growing at about 5.2% per year over the last twelve months while DHC stayed unprofitable and is expected to grow more slowly than the cited 11.2% per year US market rate, against a backdrop of trailing net losses of US$285.9 million.
• The consensus style narrative that talks about stronger senior housing and medical office demand is partly supported and partly challenged by these figures:
  • The 5.2% revenue growth rate aligns with the idea of underlying demand, yet it sits below the broader market growth number, which suggests DHC is not outpacing the wider opportunity set based on the data provided.
  • At the same time, the expectation that the company will not return to profitability in the next three years means any operational improvements described by analysts are, so far, not reflected in forecasts for net income.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Diversified Healthcare Trust on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both risks and rewards in the story so far, it makes sense to go straight to the underlying data and form your own view quickly. To weigh the concerns against the potential upsides in one place, start with the 2 key rewards and 1 important warning sign.

See What Else Is Out There

DHC combines ongoing net losses of US$285.9 million, a multi year loss trend and forecasts of continued unprofitability. This raises questions about downside risk.

If that level of uncertainty makes you uncomfortable, it could be worth shifting your focus toward companies screened for resilience and steadier profiles using the 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com